Aspira Women’s Health Regains Nasdaq Compliance
September 13, 2023 08:00 ET AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that it received written notice from the Nasdaq Stock Market LLC (“NASDAQ”) on September 12, 2023 informing the…
Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer
September 11, 2023 08:00 ET AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down…
Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford
August 31, 2023 08:00 ET Samples to be used in validating the Company’s EndoCheckSM test in development for the diagnosis of endometriosis AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement…
Aspira Women’s Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 29, 2023 08:00 ET AUSTIN, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright…
Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations
August 28, 2023 08:00 ET AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations. Ms. Snider has spent her 20+ year career in women’s healthcare and diagnostics. She…
Aspira Women’s Health® Reports Second Quarter 2023 Financial Results
August 14, 2023 16:01 ET Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuiteSM volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a decrease of 46% compared to the second quarter of 2022 Conference…
Aspira Women’s Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer
August 09, 2023 16:05 ET AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Ryan Phan, Ph.D., is stepping down as the Company’s Chief Scientific and Operating Officer…
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023
July 31, 2023 08:00 ET AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14,…
Aspira Women’s Health Announces $4.7 Million Registered Direct Offering
July 20, 2023 08:30 ET AUSTIN, Texas, July 20, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with institutional investors, alongside participation from certain longstanding…
Aspira Women’s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD
June 28, 2023 08:00 ET AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (“DECD”) has determined that Aspira satisfied…
Aspira Women’s Health Appoints Dr. Winfred Parnell to its Board of Directors
June 05, 2023 08:00 ET AUSTIN, Texas, June 05, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Dr. Winfred Parnell as a new independent director on the Aspira Board of Directors, effective…
Aspira Women’s Health Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
June 02, 2023 08:00 ET AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, announced today that it has received notification from the Listing Qualifications Department (“the Staff”) of the Nasdaq Stock Market (“Nasdaq”)…
Aspira Women’s Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
May 31, 2023 08:00 ET AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, announced the online publication of three abstracts supporting the clinical utility of OvaWatchSM at the 2023 American Society of Clinical Oncology…
Aspira Women’s Health to Participate at William Blair’s 43rd Annual Growth Stock Conference
May 30, 2023 08:00 ET AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will participate in William Blair’s 43rd Annual Growth Stock Conference taking place in Chicago, Illinois…
Aspira Women’s Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
May 19, 2023 08:00 ET AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it would present at the upcoming 2023 American College of Obstetricians and Gynecologists (“ACOG”) Annual Clinical & Scientific…
Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer
May 16, 2023 16:05 ET AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan. Dr. Hombeck brings…
Aspira Women’s Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023
May 15, 2023 16:05 ET AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it will host a virtual Investor Day on Tuesday, May 23, 2023 at 1:00pm ET. Click here to…
Aspira Women’s Health Announces 1-for-15 Reverse Stock Split
May 11, 2023 12:33 ET AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic, tools, today announced a 1-for-15 reverse stock split of its outstanding common stock, effective at 12:01 am Eastern time on May…
Aspira Women’s Health Signs an Exclusive Licensing Agreement with Dana Farber Cancer Institute for the Development of microRNA-based Ovarian Cancer Test
New blood-based test could use microRNA alone or in combination with other biomarkers for earlier diagnosis of ovarian cancer May 11, 2023 08:00 ET AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has signed an exclusive…
Aspira Women’s Health® Reports First Quarter 2023 Financial Results
May 11, 2023 16:01 ET First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time…
Aspira Women’s Health Appoints Three New Members to its Board of Directors
May 09, 2023 16:07 ET AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it the appointment of three new independent directors: Stefanie Cavanaugh, Jannie Herchuck, and Lynn O’Connor Vos. “We are…
Aspira Women’s Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
April 27, 2023 16:05 ET Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company’s history Management to host its first quarter earnings conference call on Thursday, May 11 at 4:30 pm AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) — Aspira Women’s…
Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results
March 22, 2023 16:05 ET 2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) —…
Aspira Women’s Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
March 03, 2023 08:38 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023.…
Aspira Women’s Health Announces National Payer Coverage for OvaWatch
First National Payer to Cover OvaWatch March 03, 2023 08:00 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million lives worldwide has agreed…